Here's Why Array BioPharma Inc. Fell 13.7% in July

Here's Why Array BioPharma Inc. Fell 13.7% in July

Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.

Here's a review of the two company announcements made during the month:

Given the upbeat news items, I'm once again left scratching my head as to why shares fell so much last month.

Continue reading

Source: Fool.com